Rivera, Eddie
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Molenda, John
`Friday, January 05, 2018 6:25 PM
`Frank Calvosa
`Abraxane; Harnett, Christopher J.; Insogna, Anthony M.; Miller, Cary;
`sjcorr@jonesday.com; Nick Cerrito; Andrew Chalson; Daniel Wiesner
`RE: IPR2018-00151, -152, -153
`
`Frank, 
` 
`We’ve repeatedly asked you to explain the connection between why any loss of paclitaxel in Apotex’s process would 
`inform the amount of paclitaxel loss (if any) in the asserted prior art.  Given that you refuse to answer this fundamental 
`question, our inclination is to oppose this request.  We are available for a meet and confer late Monday afternoon (after 
`4) or Tuesday morning to discuss. 
` 
`John 
` 
` 
`John Josef Molenda, Ph.D. 
`Partner 
`Co‐Chair, Healthcare & Life Sciences Practice 
`Steptoe
`Steptoe & Johnson LLP | 1114 Avenue of the Americas | New York, NY 10036 
`+1 212 378 7540 direct | +1 917 549 2189 mobile | +1 212 506 3950 fax | jmolenda@Steptoe.com | www.steptoe.com
`John Molenda’s biography  
` 
`From: Frank Calvosa [mailto:frankcalvosa@quinnemanuel.com]
`Sent: Tuesday, January 02, 2018 10:12 PM
`To: Molenda, John
`Cc: Abraxane; Harnett, Christopher J.; Insogna, Anthony M.; Miller, Cary; sjcorr@jonesday.com; Nick Cerrito; Andrew
`Chalson; Daniel Wiesner
`Subject: Re: IPR2018-00151, -152, -153
` 
`
`John, 
`
`
`
` 
`
`The discovery requested relates to real-world experience with paclitaxel loss that the Board, in its Institution Decisions,
`suggested may be appropriate for submission by the parties. As I told you previously, the Board’s suggestion was not
`limited to prior art. If you disagree and Apotex intends to oppose our request, please let us know. 
`
` 
`
`Best, 
`
`
`Frank Calvosa 
`
`1
`
`Apotex v. Abraxis - IPR2018-00152, Ex. 1027, p.01 of 5
`
`

`

`Associate  
`Quinn Emanuel Urquhart & Sullivan, LLP 
` 
`51 Madison Avenue, 22nd Floor 
`New York, NY 10010 
`+1 212‐849‐7569 Direct 
`frankcalvosa@quinnemanuel.com 
` 
`On Dec 28, 2017, at 12:28 PM, Molenda, John <jmolenda@Steptoe.com> wrote: 
`
`Frank, 
`
`  
`You still have not answered our inquiry from 12/12, namely why any loss of paclitaxel in a post‐date 
`Apotex process would inform the amount of paclitaxel loss (if any) in the asserted prior art.  Please 
`provide an answer to that question, as we need this information to fully assess your position on the 
`requested document production. 
`
`  
`Best, 
`John 
`  
`John Josef Molenda, Ph.D.  
`Partner 
`Co‐Chair, Healthcare & Life Sciences Practice 
`Steptoe 
`Steptoe & Johnson LLP | 1114 Avenue of the Americas | New York, NY 10036  
`+1 212 378 7540 direct | +1 917 549 2189 mobile | +1 212 506 3950 fax | jmolenda@Steptoe.com | 
`www.steptoe.com 
`John Molenda’s biography  
`
`  
`From: Frank Calvosa [mailto:frankcalvosa@quinnemanuel.com]
`Sent: Friday, December 22, 2017 2:39 PM
`To: Molenda, John; Abraxane
`Cc: Harnett, Christopher J.; Insogna, Anthony M.; Miller, Cary; 'sjcorr@jonesday.com'; Nick Cerrito;
`Andrew Chalson; Daniel Wiesner
`Subject: RE: IPR2018-00151, -152, -153 
`  
`John, 
`
`  
`Sorry if my email was unclear. The Board’s inquiry was not limited to a prior art process.  
`
`  
`Best, 
`
`Frank Calvosa
`Associate
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212-849-7569 Direct
`212-849-7000 Main Office Number
`212-849-7100 FAX
`frankcalvosa@quinnemanuel.com
`www.quinnemanuel.com 
`
`2
`
`Apotex v. Abraxis - IPR2018-00152, Ex. 1027, p.02 of 5
`
`

`

`NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named
`above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader
`of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you
`have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you
`have received this communication in error, please notify us immediately by e-mail, and delete the original message.  
`From: Molenda, John [mailto:jmolenda@Steptoe.com]  
`Sent: Thursday, December 21, 2017 10:50 AM 
`To: Frank Calvosa <frankcalvosa@quinnemanuel.com>; Abraxane <Abraxane@Steptoe.com> 
`Cc: Harnett, Christopher J. <charnett@jonesday.com>; Insogna, Anthony M. 
`<aminsogna@jonesday.com>; Miller, Cary <cmiller@jonesday.com>; 'sjcorr@jonesday.com' 
`<sjcorr@jonesday.com>; Nick Cerrito <nickcerrito@quinnemanuel.com>; Andrew Chalson 
`<andrewchalson@quinnemanuel.com>; Daniel Wiesner <danielwiesner@quinnemanuel.com> 
`Subject: RE: IPR2018‐00151, ‐152, ‐153 
`
`  
`Frank, 
`
`  
`Thanks for your email below.  However, to enable us to  properly assess your position, can you please 
`address the inquiries presented in our email of 12/12?  We do not see where the board said that 
`discovery of a present‐date process informs paclitaxel loss of a different prior art process.  If you are still 
`taking the position that Apotex evidence informs a prior art process, please explain why. 
`
`  
`Best, 
`  
`John   
`  
`  
`John Josef Molenda, Ph.D.  
`Partner 
`Co‐Chair, Healthcare & Life Sciences Practice 
`Steptoe 
`Steptoe & Johnson LLP | 1114 Avenue of the Americas | New York, NY 10036  
`+1 212 378 7540 direct | +1 917 549 2189 mobile | +1 212 506 3950 fax | jmolenda@Steptoe.com | 
`www.steptoe.com 
`John Molenda’s biography  
`
`  
`From: Frank Calvosa [mailto:frankcalvosa@quinnemanuel.com]
`Sent: Friday, December 15, 2017 2:00 PM
`To: Molenda, John; Abraxane
`Cc: Harnett, Christopher J.; Insogna, Anthony M.; Miller, Cary; 'sjcorr@jonesday.com'; Nick Cerrito;
`Andrew Chalson; Daniel Wiesner
`Subject: RE: IPR2018-00151, -152, -153 
`  
`John, 
`
`  
`Thanks for following up.  As set forth in Abraxis’s opposition to Joinder, when it instituted the Actavis 
`IPRs, the Board suggested that the parties submit evidence regarding loss of paclitaxel during synthesis 
`of nanoparticles.  The Board also noted that Abraxis may wish to seek discovery from petitioner 
`regarding paclitaxel loss, and again raised this issue on the Initial Scheduling Call.  Since Apotex’s 
`petition is substantially similar to Actavis’s, Abraxis is seeking similar discovery from Apotex.  Abraxis 
`submits that such discovery should be produced as routine discovery.  If Apotex does not agree, 
`however, then Abraxis will need to present the issue to the Board. 
` 
`Best, 
`
`3
`
`Apotex v. Abraxis - IPR2018-00152, Ex. 1027, p.03 of 5
`
`

`

`  
`
`Frank Calvosa
`Associate
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212-849-7569 Direct
`212-849-7000 Main Office Number
`212-849-7100 FAX
`frankcalvosa@quinnemanuel.com
`www.quinnemanuel.com 
`
`NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named
`above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader
`of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you
`have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you
`have received this communication in error, please notify us immediately by e-mail, and delete the original message.  
`  
`
`  
`From: Molenda, John [mailto:jmolenda@Steptoe.com]  
`Sent: Tuesday, December 12, 2017 6:19 PM 
`To: Frank Calvosa <frankcalvosa@quinnemanuel.com>; Abraxane <Abraxane@Steptoe.com> 
`Cc: Harnett, Christopher J. <charnett@jonesday.com>; Insogna, Anthony M. 
`<aminsogna@jonesday.com>; Miller, Cary <cmiller@jonesday.com>; 'sjcorr@jonesday.com' 
`<sjcorr@jonesday.com>; Nick Cerrito <nickcerrito@quinnemanuel.com>; Andrew Chalson 
`<andrewchalson@quinnemanuel.com>; Daniel Wiesner <danielwiesner@quinnemanuel.com> 
`Subject: RE: IPR2018‐00151, ‐152, ‐153 
`
`  
`Frank, 
`
`  
`So that we can more fully assess your request, please explain the connection between the discovery you 
`seek and the prior art grounds asserted in the petitions.  In your response, please specifically address 
`why any loss of paclitaxel in a post‐date Apotex process would inform the amount of paclitaxel loss (if 
`any) in the asserted prior art. 
`
`  
`Best, 
`John 
`  
`John Josef Molenda, Ph.D.  
`Partner 
`Co‐Chair, Healthcare & Life Sciences Practice 
`Steptoe 
`Steptoe & Johnson LLP | 1114 Avenue of the Americas | New York, NY 10036  
`+1 212 378 7540 direct | +1 917 549 2189 mobile | +1 212 506 3950 fax | jmolenda@Steptoe.com | 
`www.steptoe.com 
`John Molenda’s biography  
`
`  
`From: Frank Calvosa [mailto:frankcalvosa@quinnemanuel.com]
`Sent: Wednesday, December 06, 2017 12:01 PM
`To: Abraxane
`Cc: Harnett, Christopher J.; Insogna, Anthony M.; Miller, Cary; 'sjcorr@jonesday.com'; Nick Cerrito;
`Andrew Chalson; Daniel Wiesner
`Subject: IPR2018-00151, -152, -153 
`  
`
`4
`
`Apotex v. Abraxis - IPR2018-00152, Ex. 1027, p.04 of 5
`
`

`

`Counsel, 
`
`  
`We have received Apotex’s petitions for inter partes review (“IPR”) and accompanying motions for 
`joinder.  Based on the arguments made in your petitions (which mirror those made in the Actavis’s IPRs 
`addressing the same patents) and in view of the Board’s institution decisions in the Actavis IPRs, we 
`intend to seek limited discovery from Apotex in the IPRs.  Specifically, we plan to request:  All 
`documents and things relating to loss of paclitaxel during processing or development of any albumin‐
`bound paclitaxel nanoparticle formulation.   
`
`  
`Please let us know by close of business on Friday, December 8 if Apotex opposes this request. 
`
`  
`Best, 
`
`  
`Frank Calvosa
`Associate
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212-849-7569 Direct
`212-849-7000 Main Office Number
`212-849-7100 FAX
`frankcalvosa@quinnemanuel.com
`www.quinnemanuel.com 
`
`NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named
`above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader
`of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you
`have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you
`have received this communication in error, please notify us immediately by e-mail, and delete the original message.  
`
`5
`
`Apotex v. Abraxis - IPR2018-00152, Ex. 1027, p.05 of 5
`
`